Core Insights - PureTech has presented new data from the Phase 2b open-label extension study of Deupirfenidone, indicating its potential to become a new standard of care for Idiopathic Pulmonary Fibrosis (IPF) [1] Group 1: Study Findings - The data supports the efficacy and safety profile of Deupirfenidone in treating IPF, suggesting significant clinical benefits [1] - The study results demonstrate a favorable outcome in terms of lung function preservation and quality of life for patients [1] Group 2: Market Implications - If approved, Deupirfenidone could address a significant unmet need in the IPF treatment landscape, potentially capturing a substantial market share [1] - The findings may influence treatment guidelines and physician prescribing behavior, positioning Deupirfenidone as a preferred option for IPF management [1]